Video 4Video1Video2Video3Video4Video5Video6Video7Video8Video9Video10Video11Video12Video13(Mexico)Video14Video15(Espanol)Video16Disclaimer:
Individual results vary. Anti-TNF treatment for the indications
below is off-label. Please see the Legal Disclaimer. Maintenance dosing, usually
weekly, but sometimes as little as monthly, is necessary for optimal
effect. The methods of anti-TNF treatment utilized for these patients
are patented inventions of the INR[1].Rapid improvement within minutes and sustained
improvement following perispinal etanercept in Alzheimer's disease
(2007)* video length 6:22
This video is actual patient
footage showing the patient's clinical improvement within minutes
following initiation of perispinal etanercept at the INR, and
his sustained response through five weeks. This video is a companion
to the published editorial entitled Perispinal etanercept:
potential as an Alzheimer therapeutic. Griffin WS. Journal
of Neuroinflammation 2008 January; 5:3.The videos above are interviews discussing
and documenting the clinical response to initiation of anti-TNF
treatment (perispinal etanercept) at the INR. For
the published results please see Tobinick E, Gross H, Weinberger
A, Cohen H., TNF-alpha Modulation for Treatment of Alzheimer's
Disease: A 6-Month Pilot Study MedGenMed 2006; 8(2) :25;
Tobinick E., Perispinal etanercept for treatment of Alzheimer's
disease, Current Alzheimer Research 2007 Dec; 4(5):550-2;
Tobinick E, Gross H., Rapid improvement in verbal fluency
and aphasia following perispinal etanercept in Alzheimer's disease,
BMC Neurology 2008; 8:27; and Tobinick E., Perispinal
etanercept for neuroinflammatory disorders, Drug Discovery
Today 2009 Feb; 14(3-4):168-77.Institute for Neurological Research, a private medical group, inc.
100 UCLA Medical Plaza, Suites 205-210 Los Angeles, California
90095
Video2